TP53 and breast carcinoma: To further validate the competitive growth assay, we used two BRCA1 isogenic cell line pairs; the BRCA1-deficient SUM149 breast cancer cell lines (as mentioned above) and a pair of retinal pigment epithelial cells (RPE) p53-/- with and without BRCA1 knocked out.